Rocket Pharmaceuticals (RCKT) Interest Expenses (2014 - 2026)

Rocket Pharmaceuticals has reported Interest Expenses for 13 years, with the latest figure at $473000.0 in Q1 2026.

• Quarterly Interest Expenses changed 0.21% year-over-year to $473000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (changed 0.21% YoY) and the FY2025 annual result came in at $133.1 million, up 3.11% from the prior year.
• Interest Expenses held at $473000.0 in Q1 2026 per RCKT's latest filing, from $473000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $127.1 million in Q3 2023 and troughed at $467000.0 in Q4 2022.
• A 5-year average of $40.6 million and a median of $473000.0 in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses tumbled 99.63% in 2024, then soared 10058.6% in 2025.
• Over 5 years, Interest Expenses stood at $467000.0 in 2022, then increased by 0.64% to $470000.0 in 2023, then grew by 0.64% to $473000.0 in 2024, then changed by 0.0% to $473000.0 in 2025, then changed by 0.0% to $473000.0 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $473000.0, $473000.0, and $47.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.